The statistical design assumed an -improvement of 25% with T-DM1. The efficacy stopping boundary for the single, prespecified boundary for early reporting ...
Tucatinib is a HER2-selective tyrosine kinase inhibitor. As an oral agent, tucatinib may be associated with fewer side effects than other such inhibitors.
... Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine ( T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2018 ASCO Annual Meeting
1: Treatment approach for patient presenting with HER2-positive metastatic breast cancer in 2013. Courtesy of Eric P. Winer, MD.
Expression of CTLA-4, PD-1, and PD-L1 and combination therapy of T-DM1... | Download Scientific Diagram
Preferential targeting of clonogenic breast cancer cells by T-DM1. (a) HER2-positive breast cancer cells (left: SK-BR-3, right: BT-474) were treated for 48 ...
Table 3 Ongoing clinical trials of peptide- and DC-based vaccine immunotherapeutics in breast cancer
CORRECTING and REPLACING Seattle Genetics Announces Publication of Results from Two Tucatinib Phase 1b Clinical Trials in HER2-Positive Metastatic Breast ...
During coculture with NK cells, T-DM1 can induce ADCC in breast cancer... | Download Scientific Diagram
Ado-trastuzumab Emtansine a Potential New Treatment Option for HER2-Amplified Advanced Salivary Gland Cancer
Acquired T-DM1 resistance is characterized by loss of T-DM1-induced mitotic arrest, apoptosis and DNA damage in HER2-positive breast cancer. a Dose–response ...
Trastuzumab Emtansine Improves Survival in Previously Treated Metastatic HER2-Positive Breast Cancer
Effectors of EGFR/HER2 downstream signaling pathways and corresponding effective potential clinical drugs. ATA, acetyltanshinone IIA; AE, aloe-emodin; ...
Frontiers | Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy | Immunology
Among female patients with CML, fertility preservation with ovarian stimulation can be challenging i
Pretreatment with trastuzumab in HER-2-positive cells up-regulated caveolin-1 expression and improved T-DM1 drug efficacy. (A) Treatment of BT-474 cells ...
About one-third of patients will experience disease recurrence after undergoing nephrectomy, and cli
... type #HER2 and the variant d16her2 in tumor context of multiple cancer types #breastcancer @SciReports http://bit.ly/2WnF7Rl pic.twitter.com/DRSqgQiAXu
DRUGS used for Her 2 neu + Breast Cancer Brand Name Generic name. Taxol = paclitaxel. Taxotere = docetaxol. Xeloda = capecitabine
Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches - Oncology Nurse Advisor
Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations
In vitro efficacy of T-DM1 combined with pertuzumab on cell proliferation and apoptosis. (a and c) Inhibition of cell growth induced by pertuzumab (40 ...
In a case report of a previously treated patient with NSCLC harboring an exon 20 HER2 mutation, off-label use of afatinib therapy was administered.
Trastuzumab emtansine (T-DM1) is currently approved for the treatment of patients with HER2-positive metastatic breast cancer after failure of prior ...
Structure of trastuzumab emtansine and mechanisms of action. Notes: On binding of trastuzumab emtansine
genentech submits supplemental biologics license application to fda for kadcyla for adjuvant treatment of people with
Clinical trials of pertuzumab-based and ado-TrastuzumabEmtansine therapy for the treatment of HER2-overexpressing advanced or metastatic gastric cancer.
Table 3 Pivotal undergoing clinical trials of ribociclib or LEE011 for the treatment of various cancers (www.clinicaltrials.gov)
OncLive: What are some of the key takeaways from your discussion of the evolving treatment landscape in HER2-positive breast cancer?
Inhibition of HER2-signal transduction after the triple-drug treatment. Lysates from tumor tissues collected 4 days after starting treatment were used for ...
Figure 1. Consolidated Standards of Reporting Trials (CONSORT) Chart of the Herceptin Adjuvant (HERA) Trial.
Adam Brufsky, MD, PhD, on HER2-Positive Metastatic Breast Cancer: NALA Trial on Neratinib vs Lapatinib Plus Capecitabine